PTPI
Petros Pharmaceuticals, Inc. [PTPI] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
PTPI Stock Summary
Top 10 Correlated ETFs
PTPI
Top 10 Correlated Stocks
PTPI
In the News
PTPI Financial details
Company Rating
-
Market Cap
5.73M
Income
-226.18M
Revenue
5.82M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
21
Optionable
No
Shortable
Yes
Earnings
29 May 2024
P/E
-0.01
Forward P/E
-
PEG
-0
P/S
0.42
P/B
0.41
P/C
-
P/FCF
-0.44
Quick Ratio
2.59
Current Ratio
3.02
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-108.39
EPS next Y
-
EPS next Q
-
EPS this Y
-71.29%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-54.41%
Revenue last 5Y
-17.87%
Revenue Q/Q
-121.75%
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-97.39%
SMA100
-99.56%
Inst Own
-
Inst Trans
-
ROA
-593%
ROE
-1774%
ROC
-0.41%
Gross Margin
66%
Oper. Margin
-182%
Profit Margin
-3303%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.813-9.54
52W High
-
52W Low
-
RSI
30.12
Rel Volume
0.21
Avg Volume
1.15M
Volume
245.1K
Perf Week
16.67%
Perf Month
-71.77%
Perf Quarter
-99.62%
Perf Half Y
-99.7%
-
-
-
-
Beta
2.24
-
-
Volatility
0%, 0.01%
Prev Close
0%
Price
0.035
Change
-2.78%
Company Profile
- Volume Average 1.15M
- Market Capitalization 5.73M
- Employee 21
- CEO Mr. John David Shulman
- Headquarters New York,NY,US
- IPO Date 2020-12-02
-
Website
https://www.petrospharma.com 
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
